Answer ALS is proud to announce the launch of a groundbreaking collaborative initiative aimed at accelerating AI-powered drug discovery for ALS and other neurodegenerative diseases. This effort, known as the Louisiana AI Drug Development Infrastructure for ALS (LADDIA), brings together leading institutions and innovators, including GATC Health, Pennington Biomedical Research Center, and Tulane University —  a tech-bio innovator using validated AI models to accelerate drug discovery from large-scale multiomics data —  to harness the power of artificial intelligence and one of the largest ALS datasets in the world. 

The largest (self-selected) survey of  people living with eating disorders has revealed some surprising insights into how people view prescription and (self-medicated) non-prescription drugs. Psychedelics and cannabis were highest rated, with the research team now taking next steps for clinical trials.

New research from the University of Pittsburgh reveals how the immune system defends against intestinal parasitic worms, or helminths, one of the most common infections worldwide in communities with limited access to clean water and sanitation.

A molecular pathway used by pancreatic cancer cells to adapt to stress and inflammation could lead to earlier detection and treatment of the deadly disease.